2024
Improving access to first‐line treatment for pediatric obesity: Lessons from the dissemination of SmartMoves
Finn E, Keller C, Gowey M, Savoye M, Samuels S, Fleisch A, Rogers V, Grey M, Damschroder L, Beck A, Sharifi M. Improving access to first‐line treatment for pediatric obesity: Lessons from the dissemination of SmartMoves. Obesity 2024, 32: 1745-1756. PMID: 39192771, DOI: 10.1002/oby.24107.Peer-Reviewed Original ResearchConceptsConstant comparative methodInterviewed key informantsHealth behaviorsObesity programsSufficient staffingInsufficient staffingPediatric obesityFunding insecurityLifestyle treatmentImprove accessOrganizational prioritiesProgram componentsProgram fitPromote fidelityKey informantsUS sitesIncreased prevalenceAdequate fundingSurvey findingsStaffingParticipantsInterviewsCOVID-19 pandemicDominant barriersObesity
2023
Rising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States
Slusher A, Hu P, Samuels S, Tokoglu F, Lat J, Li Z, Alguard M, Strober J, Vatner D, Shabanova V, Caprio S. Rising NAFLD and metabolic severity during the Sars‐CoV‐2 pandemic among children with obesity in the United States. Obesity 2023, 31: 1383-1391. PMID: 36694381, PMCID: PMC10186584, DOI: 10.1002/oby.23728.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseOral glucose tolerance testGlucose tolerance testProton density fat fractionLiver diseaseSars-Cov-2 pandemicTolerance testSeverity of NAFLDMagnetic resonance imaging-derived proton density fat fractionFrequency-matched control groupIntrahepatic fat contentCommon liver diseaseFatty liver diseasePediatric obesity clinicVisceral adipose tissueGlobal pandemicNAFLD prevalenceObesity clinicMetabolic severityInsulin secretionAdipose tissueControl groupObesityPatient careHealth differences